In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Northwest Biotherapeutics, Inc.

http://www.nwbio.com/

Latest From Northwest Biotherapeutics, Inc.

Urovant’s Vibegron Flops In IBS Study

Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.

Clinical Trials Companies

Deal Watch: Lilly Finds New Partners For Genetic Disorders, Protein Degradation

Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.

Deals Business Strategies

Vifor Builds Its Kidney Disease Focus With $80m Angion Deal

Deal helps Vifor pursue goal of becoming a leader in kidney disease therapies.

Companies Commercial

Finance Watch: CureVac’s IPO Is Ready For Launch

Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m. 

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Other Names / Subsidiaries
    • NW Bio
UsernamePublicRestriction

Register